The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle ...

The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...